Akeso says ivonescimab meets overall survival endpoint in Phase III HARMONi-2 lung cancer trial

• Akeso reported its Phase III HARMONi-2 trial met a key overall survival endpoint in an interim analysis versus Merck’s pembrolizumab.
• Findings showed a statistically significant, clinically meaningful survival benefit for first-line PD-L1-positive advanced non-small cell lung cancer.
• Detailed interim results have not been presented yet; disclosure is slated for a future international medical conference and journal publication.
• The same study previously cleared its main progression-free survival endpoint, supporting the drug’s competitive positioning against a standard-of-care PD-1 therapy.
• China has already cleared this use, expanding access to a chemotherapy-free option across both squamous and non-squamous patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609021700PR_NEWS_USPR_____CN39384) on September 02, 2026, and is solely responsible for the information contained therein.